Entries by surrozen

Surrozen Appoints Dr. Trudy Vanhove as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., April 11, 2019 (GLOBE NEWSWIRE) — Surrozen Inc., a company discovering and developing novel antibodies for regenerative medicine with a focus on specific control of the Wnt signaling pathway, today announced the appointment of Trudy Vanhove, MD, PhD, MBA, as Chief Medical Officer. An experienced biopharmaceutical executive, Dr. Vanhove brings to […]

Surrozen Raises $50 Million in Series B Financing to Advance Regenerative Antibody Platforms and Liver Disease Candidates

— Anna Berkenblit, MD, appointed to Surrozen Board of Directors — SAN FRANCISCO, March 14, 2019 (GLOBE NEWSWIRE) — Surrozen Inc., a company discovering and developing novel antibodies for regenerative medicine with a focus on specific control of the Wnt signaling pathway, today announced the successful completion of a $50 million Series B financing. The […]

Surrozen Strengthens Leadership Team with Addition of New CEO and Scientific Co-founder

SAN FRANCISCO, April 4, 2018 /PRNewswire/ — Surrozen, a preclinical-stage company advancing drug candidates that promote the repair and regeneration of human tissues, today announced two appointments to expand its leadership team.  Craig Parker, a biotech industry veteran recently of Jazz Pharmaceuticals, has been appointed CEO, and Hans Clevers, M.D., Ph.D., professor of molecular genetics at the Hubrecht Institute, […]

Surrozen Launches Into Regenerative Medicine With $33 Million in Series A Financing Led by The Column Group

— Founded on key discoveries from Stanford University that enable selective Wnt pathway activation, Surrozen advances novel regenerative medicines with broad applications for human health — SOUTH SAN FRANCISCO, Calif., Feb. 15, 2017 /PRNewswire/ — Surrozen Inc., a newly formed biopharmaceutical company focused on discovering and developing drugs that promote the repair and regeneration of human tissues, has […]